| Name | Katahdin Nursing Home |
|---|---|
| Location | 22 Walnut Street, Millinocket, Maine |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 36 |
| Occupancy Rate | 74.44% |
| Medicare ID (CCN) | 205149 |
| Legal Business Name | Katahdin Health Care Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1003149212 |
| Organization Name | KATAHDIN HEALTH CARE LLC |
| Address | 22 Walnut St, Millinocket, ME 04462 |
| Phone Number | 207-723-4711 |
News Archive
Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).
A study by University of North Carolina at Chapel Hill researchers found that 31 radiologists who reviewed the CT scans used in a medical malpractice lawsuit did not agree with the conclusions reached by four paid medical expert witnesses in the case.
Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients.
A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).
A study by University of North Carolina at Chapel Hill researchers found that 31 radiologists who reviewed the CT scans used in a medical malpractice lawsuit did not agree with the conclusions reached by four paid medical expert witnesses in the case.
Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients.
A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.91 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 13.33 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 65.63 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.05 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 14.84 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.53 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.18 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 29.01 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 47.62 | 83.88 |